期刊文献+

原癌基因Pokemon的克隆原核表达及纯化 被引量:1

Cloning,prokaryotic expression and purification of proto-oncogene Pokemon
下载PDF
导出
摘要 目的克隆小鼠Pokemon(POKeryhroidmyeloidontogenicfactor)基因并进行原核表达及重组蛋白的纯化。方法应用反转录聚合酶链反应(RT-PCR)扩增目的基因片段,克隆人pGEM-T-easy载体,经鉴定后,以限制性核酸内切酶分别消化重组质粒及原核表达载体pET-30a(+),体外定向连接,进行PCR、内切酶酶切及DNA序列分析,阳性重组表达质粒进一步转化到大肠杆菌E.coliBL21(DE3)中诱导表达,经Ni-NTA亲和层析纯化融合蛋白,Westernblotting检测其特异性。结果限制性核酸酶切及序列分析表明重组表达质粒包含Pokemon基因编码区,阅读框架无移位;十二烷基磺酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)显示有预期相对分子质量为36000的重组蛋白表达,经亲和层析纯化后,融合蛋白的纯度达到90%以上;Westernblotting印迹表明纯化的融合蛋白具有特异的免疫反应特性。结论采用基因克隆技术成功构建了Pokemon原核表达载体,并获得了高纯度的重组蛋白,为后期抗体的制备及进一步研究该基因与肿瘤发生的关系奠定了基础。 Objective To clone mouse Pokemon gene and to induce its expression in E.coli,further to purify the recombinant protein. Methods Target gene was amplified by reverse transcription polymerase chain reaction(RTPCR) and cloned into pGEM-T-easy.After being identified,the recombinant plasmid was digested and cloned into prokaryotic expression vector pET-30a(+) which was digested with the same restriction enzymes.PCR, retriction enzyme digestion and direct sequencing were used to identify the positive recombinant expression plasmid which was transformed into the E.coli BI21 (DE3) and induced to express recombinant protein.The fusion protein was further purified with Ni-NTA affinity chromatography and confirmed with Western blotting. Results Restriction enzyme digestion and DNA sequencing suggested that the recombinant expression plasmid contained correct encoding region of Pokemon, without reading frame shift.SDS-PAGE demonstrated that the recombinant protein was highly expressed with the expected molecular weight at 36 000 and the purity of the fusion protein was above 90% after being purified with affinity chromatography.Western blotting also demonstrated the immune specificity of the purified fusion protein. Conclusion The prokaryotic expression vector of Pokemon is successfully constructed by gene cloning technique,and its recombinant protein with high purity was obtained.These results may play basic roles for antibody preparation and further study into the relationship between Pokemon and tumorigenesis.
出处 《中国药物与临床》 CAS 2006年第8期576-579,共4页 Chinese Remedies & Clinics
基金 山西省自然科学基金资助项目(20021101)
关键词 原癌基因 遗传载体 原核表达 Proto-oncogenes Genetic vector Prokaryotic expression
  • 相关文献

参考文献13

  • 1徐宁志,程书钧.恶性肿瘤癌变机理及早期诊治与预防的基础研究[J].生命科学,2005,17(6):477-478. 被引量:5
  • 2Maeda T,Hobbs RM,Merghoub T,et al.Role of the protooncogene Pokemon in cellular transformation and ARF repression.Nature,2005,433(7023):278-285.
  • 3Maeda T,Hobbs RM,Pandolfi PP.The transcription factor pokemon:a new key player in cancer pathogenesis.Cancer Res,2005,65(19):8575-8578.
  • 4Davies JM,Hawe N.Novel BtB-poz domain zine-finger protein,LRF,is a popential target of the LAZ-3/Bcl-6 oncogene.Qncogene,1999,18(2):365-375.
  • 5Marchini S,D' Incalci M,Broggini M.New molecules and strategies in the field of anticancer agents.Curr Med Chem Anticancer Agents,2004,4(3):247-262.
  • 6Tsuruo T,Naito M,Tomida A,et al.Molecular targeting therapy of cancer:drug resistance,apoptosis and survival signal.Cancer Sci,2003,94(1):15-21.
  • 7罗荣城,尤长宣.肿瘤生物治疗新进展[J].中国新药杂志,2005,14(2):143-146. 被引量:18
  • 8Piccart-Gebhart MJ.Herceptin:the future in adjuvant breast cancer therapy.Anticancer Drugs,2001,12(Supp14):27-33.
  • 9张蓓,朱立勤.乳腺癌药物治疗的研究进展[J].中国药物与临床,2004,4(8):616-619. 被引量:5
  • 10Chin L,Pomerantz J,de Pinho RA.The INK4a/ARF tumor suppressor:one gene-two products-two pathways.Trends Biochem Sci,1998,23(8):291-296.

二级参考文献55

  • 1[1]Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002.Cancer J Clin, 2002, 52( 1 ): 23.
  • 2[5]Robert N, Leyland-Jones B, Asmar L, et al. Phase Ⅲ comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advance breast cancer. Breast Cancer Res Treat, 2002, 76(Supple): 37.
  • 3[6]Henderson C, Berry DA, Denetri GD, et al. Improved outcomes form adding sequential paclitaxel but not form escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol, 2003, 21 (6):976.
  • 4[8]Talbot DC, Moiseyenko V, van Belle S, et al. Randomised, phase Ⅱ trial comparing oral capecitabine (xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer, 2002, 86(9): 1367.
  • 5[9]O′ Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthra cycline-pretreated patients with advanced breast cancer: phase Ⅲ trial results. J Clin Oncol, 2002, 20(12): 2812.
  • 6[10]Venturini M, Durando A, Garrone O, et al. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. Cancer, 2003, 97(5):1174.
  • 7[11]Biganzoil L, Martin M, Twelves C. Moving forward with capecitabine: a glimpse of the future. Oncologist, 2002, 7 (Suppl 6):29.
  • 8[14]The ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal womem with early breast cancer: first results of the ATAC randomized trial. Lancet, 2002, 359: 2131.
  • 9[15]Nahboltz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen, a first line therapy for advanced breast cancer in postmenopausal women: results of a north American multicenter randomized trial. J Clin Oncol, 2000, 18(22): 3758.
  • 10[16]Buzdar AU. New generation aromatase inhibitors from the advance to the adjuvant setting. Breast Cancer Res Treat, 2002, 75(Suppl 1): 13.

共引文献29

同被引文献12

  • 1邓一静,倪兵,姜曼,杨玓,李凡,吴玉章.Pokemon基因siRNA逆转录病毒重组表达质粒的构建及鉴定[J].免疫学杂志,2006,22(2):203-205. 被引量:11
  • 2崔明,徐海,杨彦.Pokemon蛋白在乳腺癌中的表达及意义[J].临床外科杂志,2007,15(6):399-401. 被引量:23
  • 3Morrison DJ,Pendergrast PS,Stavropoulos P,et aL.FBI a factor that binds to the HIV-1 inducer of short transcripts(IST),is a poz domain protein[].Nucleic Acids Research.1999
  • 4Chen WY,Zeng X,Carter MG et aL.Heterozygous disruption of Hicl predisposes mice to a genderdependent Spectrum of malignant tumors[].Nature Genetics.2003
  • 5Smith KS,Chanda SK,Ungbeek M,et al.Bmi21 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic pro-genitors by E2a-Pbxl[].Molecular Cell.2003
  • 6Davies JM,Hawe N,Kabarowsli J,et al.Novel BTB/POZ domain zinc-finger protein,LRF,is a potential target of the LAZ-3/BCL-6 oncogene[].Oncegene.1999
  • 7Maeda T,Hobbs RM,Merghoub T,et al.Role of the proto-oncogene pokemon in cellular transformation and ARF repression[].Nature.2005
  • 8Adhikary S,Eilers M.Transcriptional regulation and transformation by Myc proteins[].Nature Reviews Molecular Cell Biology.2005
  • 9Kamijo T,Bodner S,Van de Kamp E,et al.Tumor spectrum in ARF-deficient mice[].Cancer Research.1999
  • 10Serrano M,Hannon GJ,Beach D.A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4[].Nature.1993

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部